We are live on ! Find out more
CVKD icon

Cadrenal Therapeutics
CVKD

2 hedge funds and large institutions have $68 invested in Cadrenal Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.18% less ownership

Funds ownership: 2.19% → 0% (-2.2%)

78% less funds holding

Funds holding: 9 → 2 (-7)

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

100% less capital inflows, than outflows

Capital inflows: $201 | Capital outflows: $165K

Holders
2
Holders Change
-7
Holders Change %
-77.78%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$201

Top Sellers

Rank Fund Capital Flow
1
Avantax Planning Partners
Avantax Planning Partners
Iowa
-$53.3K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$28.9K
3
Renaissance Technologies
Renaissance Technologies
New York
-$28K
4
Citadel Advisors
Citadel Advisors
Florida
-$25.6K
5
Virtu Financial
Virtu Financial
New York
-$12K

CVKD Hedge Fund Activity: Q3 2024 in Review

2 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q3 2024, worth a combined $68 — down 100% from $165K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of CVKD and 1 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $201. The largest seller was Avantax Planning Partners, exiting entirely with an estimated $53.3K sold.

  • 2 institutional investors held Cadrenal Therapeutics (CVKD) as of Q3 2024, down from 9 in Q2 2024.
  • Funds reported $68 of Cadrenal Therapeutics stock for Q3 2024, down 100% quarter-over-quarter.
  • 1 fund opened new Cadrenal Therapeutics positions in Q3 2024 and 8 closed out, a net change of -7 holders.
  • The largest Cadrenal Therapeutics buyer in Q3 2024 was Royal Bank of Canada, an estimated $201 added.
  • The largest Cadrenal Therapeutics seller in Q3 2024 was Avantax Planning Partners, an estimated $53.3K sold.

Based on aggregated 13F filings for Q3 2024.